Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 3,775 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 2 Diabetes Clear all
Recruiting No phase listed Observational

A Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United States

NCT07260110
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Teplizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
8 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 25, 2026, 4:12 PM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

NCT02072096
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
65 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 25, 2026, 4:12 PM EDT
Recruiting Not applicable Interventional

NOURISH - A Healthcare-community Partnership to Improve Nutrition for Optimal Glycemic Control and Pregnancy Outcomes With Pregestational Diabetes

NCT07560813
View directory record Official record
Conditions
Type 2 Diabetes, Type 1 Diabetes, Pregnancy, High Risk
Interventions
Mid-Ohio Food Farmacy (MOF+) produce delivery, Nutrition education with Dining with Diabetes (DWD), Health Impact Ohio Central Ohio Pathways Hub to address unmet social needs
Dietary Supplement · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 25, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes

NCT03005288
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BYM338 10 mg/kg, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Anaheim, California • Miami, Florida • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 25, 2026, 4:12 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Fatty Acid Radiotracer Comparison Study in Heart Failure Patients

NCT01648296
View directory record Official record
Conditions
Heart Failure, Obesity, Type 2 Diabetes Mellitus, Health Normal Volunteer Subjects
Interventions
[18F]FluorbetaOx
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 25, 2026, 4:12 PM EDT
Recruiting Phase 1 Interventional

THC Effects on Glucose in Type 2 Diabetes

NCT05322213
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
THC, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 25, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

NCT02058160
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
108
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 25, 2026, 4:12 PM EDT
Terminated Not applicable Interventional Results available

Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care

NCT03626623
View directory record Official record
Conditions
Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
Cytal Wound Matrix 1-Layer, Standard of Care (SOC)
Device · Other
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Fresno, California • New Orleans, Louisiana • Hyattsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 25, 2026, 4:12 PM EDT
Recruiting Phase 3 Interventional

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

NCT07392190
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Eloralintide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Physical Activity in Youth: Implications for Reversing Risk Factors for Type 2 Diabetes

NCT00739180
View directory record Official record
Conditions
Abdominal Obesity
Interventions
Control, Resistance Exercise, Aerobic exercise
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 18 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 25, 2026, 4:12 PM EDT
Terminated Phase 4 Interventional Results available

Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery

NCT01970462
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hyperglycemia
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
Kathleen Dungan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 25, 2026, 4:12 PM EDT
Not listed No phase listed Observational

Salivary Transcriptome Biomarkers for Early Diabetes Detection

NCT02673762
View directory record Official record
Conditions
Pre-diabetes, Type II Diabetes, Insulin Resistance
Interventions
Not listed
Lead sponsor
PeriRx
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 25, 2026, 4:12 PM EDT
Completed Phase 3 Interventional

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

NCT06066515
View directory record Official record
Conditions
Obesity
Interventions
survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Spring Valley, California • Walnut Creek, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 25, 2026, 4:12 PM EDT
Completed Not applicable Interventional Results available

Decreasing Stress in Diabetes

NCT04016415
View directory record Official record
Conditions
Stress, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions
Mindfulness Based Stress Reduction, Stress Management Education
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 25, 2026, 4:12 PM EDT
Completed No phase listed Observational

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

NCT00806520
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
5
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 25, 2026, 4:12 PM EDT
Enrolling by invitation Not applicable Interventional

PLAY2CONTROL Study

NCT07556679
View directory record Official record
Conditions
Type 2 Diabetes, Obesity & Overweight
Interventions
Nex Playground Activity Program
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
5 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

NCT01177813
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
27
States / cities
Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 25, 2026, 4:12 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

NCT04657003
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Obesity
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
938 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
43
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 25, 2026, 4:12 PM EDT
Completed Phase 2 Interventional

Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM

NCT02581657
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PE0139 Injection, Placebo Injection
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Anniston, Alabama • Huntington Park, California • Bradenton, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 25, 2026, 4:12 PM EDT
Completed Not applicable Interventional

Glycemic Response in Adults With Type 2 Diabetes

NCT05166200
View directory record Official record
Conditions
Glycemic Control
Interventions
Experimental Formula, Test Meal
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
21 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Gurnee, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 25, 2026, 4:12 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

NCT06657209
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
Interventions
Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, Pioglitazone
Procedure · Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 25, 2026, 4:12 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overwt/Obese Adults

NCT01951287
View directory record Official record
Conditions
Blood Glucose, Blood Insulin
Interventions
Acute beverage (water) consumption, Acute beverage (Black Coffee) consumption, Acute beverage (Orange Juice) consumption, Acute beverage (Whole Milk) consumption, Acute beverage (2% Milk) consumption, Acute beverage (Skim Milk) consumption
Other
Lead sponsor
Purdue University
Other
Eligibility
35 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 25, 2026, 4:12 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

NCT03449199
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
TMX-049, Placebo
Drug
Lead sponsor
Teijin America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
55
States / cities
Flagstaff, Arizona • Mesa, Arizona • Alhambra, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 25, 2026, 4:12 PM EDT
Completed Not applicable Interventional Results available

A Randomized Study to Evaluate the Efficacy of Insulclock® in Patients With Uncontrolled Type 2 Diabetes

NCT03224234
View directory record Official record
Conditions
Diabetes
Interventions
Insulclock with feedback, Insulclock without feedback
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 25, 2026, 4:12 PM EDT